REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 3
- Part 3: For the preceding part double click ID:nRSH4027Rb
product. Expiry or loss of these rights can materially adversely affect
our revenues and financial condition due to the launch of generic copies
of the product in the country where the rights have expired or been lost
(see the Patent Expiries section on pages 210 and 211, which contains a
table of certain patent expiry dates for our key marketed products).
Products protected by our IP account for a significant proportion of our
revenues. For example, in 2015, US Product Sales for Crestor and Seroquel
XR were $2,844 million (2014: $2,918 million) and $716 million (2014:
$738 million), respectively. Additionally, the expiry or loss of patents
covering other innovator companies' products may also lead to increased
competition and pricing pressure for our own, still-patented, products in
the same product class due to the availability of lower priced generic
- More to follow, for following part double click ID:nRSH4027RdRecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
Announcement